pembrolizumab,enfortumab vedotin
seagen,bicycle therapeutics,astellas,merck
['ev-302', 'dance', '$sgen', '$bcyc']
catching up on updated $bcyc nectin-4 data at asco gu. mgmt thinks aa still possible in both late stage and 1st l perhaps relying on aa guidance below when therapy already available given potential similar/greater efficacy &amp; less tox. $sgen ev-302 readout expected by ye 23 
Biotech investor